120 related articles for article (PubMed ID: 16684712)
21. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
22. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.
Zhang H; Zhang D; Li W; Yao M; D'Arienzo C; Li YX; Ewing WR; Gu Z; Zhu Y; Murugesan N; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 May; 35(5):795-805. PubMed ID: 17303626
[TBL] [Abstract][Full Text] [Related]
23. First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
Brussee JM; Yu H; Krekels EHJ; de Roos B; Brill MJE; van den Anker JN; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):374-383. PubMed ID: 29745466
[TBL] [Abstract][Full Text] [Related]
24. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
25. Dose-dependent pharmacokinetics of midazolam in rats: influence of hepatic first-pass metabolism.
Li R; Wang Q; Liu Z; Xie L; Diao Z; Peng Y; Wang G; Sun J
Xenobiotica; 2023 Mar; 53(3):184-192. PubMed ID: 37042732
[TBL] [Abstract][Full Text] [Related]
26. Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Karibe T; Imaoka T; Abe K; Ando O
Drug Metab Dispos; 2018 May; 46(5):667-679. PubMed ID: 29358184
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
[TBL] [Abstract][Full Text] [Related]
28. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
Tomalik-Scharte D; Doroshyenko O; Kirchheiner J; Jetter A; Lazar A; Klaassen T; Frank D; Wyen C; Fätkenheuer G; Fuhr U
Eur J Clin Pharmacol; 2008 Oct; 64(10):1033-5. PubMed ID: 18587567
[No Abstract] [Full Text] [Related]
29. First-pass metabolism of 5-fluorouracil in rats.
Yuasa H; Gu J; Hayashi Y; Watanabe J
J Pharm Pharmacol; 1998 Sep; 50(9):1019-25. PubMed ID: 9811163
[TBL] [Abstract][Full Text] [Related]
30. Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys.
McMahon LR; France CP
Psychopharmacology (Berl); 2005 Apr; 178(4):400-9. PubMed ID: 15765255
[TBL] [Abstract][Full Text] [Related]
31. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
33. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
34. Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models.
Zhao C; Ying Z; Hao D; Zhang W; Ying X; Yang G
Biopharm Drug Dispos; 2019 Apr; 40(3-4):112-120. PubMed ID: 30739353
[TBL] [Abstract][Full Text] [Related]
35. A PBPK model for midazolam in four avian species.
Cortright KA; Wetzlich SE; Craigmill AL
J Vet Pharmacol Ther; 2009 Dec; 32(6):552-65. PubMed ID: 20444010
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats.
Kanazu T; Okamura N; Yamaguchi Y; Baba T; Koike M
Xenobiotica; 2005 Apr; 35(4):305-17. PubMed ID: 16019953
[TBL] [Abstract][Full Text] [Related]
37. A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Tahara H; Watanabe M; Hasegawa M
Biopharm Drug Dispos; 2019 Feb; 40(2):81-93. PubMed ID: 30724384
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
Uehara S; Inoue T; Utoh M; Toda A; Shimizu M; Uno Y; Sasaki E; Yamazaki H
Xenobiotica; 2016; 46(2):163-8. PubMed ID: 26114209
[TBL] [Abstract][Full Text] [Related]
39. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
40. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
